Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Duvelisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Secura Bio to keep offering blood cancer drug despite negative ODAC vote
    Secura Bio to keep offering blood cancer drug despite negative ODAC vote

    23 Mar 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/secura-bio-to-keep-offering-blood-cancer-drug-despite-negative-odac-vote-os-questions/

    Zachary Brennan ENDPTS
    23 Mar 2023
    Share Share
    Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib
    Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib

    09 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/secura-bio-inc-receives-orphan-drug-designation-in-europe-for-duvelisib-for-the-treatment-of-patients-with-peripheral-t-cell-lymphoma-301713925.html

    PR NEWSWIRE
    09 Jan 2023
    Share Share
    FDA threatens to clamp down on another PI3K blood cancer drug—a full approval
    FDA threatens to clamp down on another PI3K blood cancer drug—a full approval

    23 Sep 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/fda-threatens-clamp-down-another-pi3k-blood-cancer-drug-time-full-approval

    Angus Liu FIERCEPHARMA
    23 Sep 2022
    Share Share
    PI3K inhibitor hit with an increased death risk warning from FDA
    PI3K inhibitor hit with an increased death risk warning from FDA

    01 Jul 2022

    // Zachary Brennan ENDPTS

    https://endpts.com/pi3k-inhibitor-hit-with-an-increased-death-risk-warning-from-fda-after-final-trial-results-emerge/

    Zachary Brennan ENDPTS
    01 Jul 2022
    Share Share
    FDA Warns of Increased Mortality Risk With Duvelisib
    FDA Warns of Increased Mortality Risk With Duvelisib

    01 Jul 2022

    // Mike Bassett MEDPAGETODAY

    https://www.medpagetoday.com/hematologyoncology/leukemia/99556

    Mike Bassett MEDPAGETODAY
    01 Jul 2022
    Share Share
    SECURA BIO ANNOUNCES PRESENTATION OF COPIKTRA DATA FOR PTCL
    SECURA BIO ANNOUNCES PRESENTATION OF COPIKTRA DATA FOR PTCL

    14 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/secura-bio-announces-the-presentation-of-new-copiktra-duvelisib-data-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas-ptcl-301444094.html

    PRNEWSWIRE
    14 Dec 2021
    Share Share